Non-Small Cell Lung Carcinoma TNM clinical staging | Disease Amenable Biopsy
Item
patient must have histologically confirmed stage i-iiia non-small cell lung cancer (nsclc) which is accessible to biopsy.
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C3900053 (UMLS CUI [2,2])
C0005558 (UMLS CUI [2,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life-expectancy greater than 6 months.
boolean
C0023671 (UMLS CUI [1])
Bone Marrow function | Renal function | Liver function | Pulmonary function | Cardiac function
Item
adequate bone marrow, renal, hepatic, pulmonary and cardiac function as defined in the protocol.
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0231921 (UMLS CUI [4])
C0232164 (UMLS CUI [5])
Age
Item
patient must be at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Protocol Compliance
Item
must meet pre-entry requirements for timing of study parameters as specified in section 7.0.
boolean
C0525058 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Breast Feeding Absent
Item
female patients of child-bearing potential must have a negative serum pregnancy test within 48 hours of study initiation and be non-lactating.
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0006147 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Childbearing Potential Contraceptive methods
Item
patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Granulocyte Colony-Stimulating Factor
Item
the use of granulocyte-colony stimulating factor (g-csf) will be permitted in study participants.
boolean
C0079459 (UMLS CUI [1])
Eligibility Determination Medical research personnel
Item
final eligibility for a clinical trial is determined by the health professionals conducting the trial.
boolean
C0013893 (UMLS CUI [1,1])
C3826005 (UMLS CUI [1,2])
Therapeutic procedure Non-Small Cell Lung Carcinoma
Item
patient has received previous treatment for nsclc.
boolean
C0087111 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
Hypersensitivity everolimus | Hypersensitivity Sirolimus | Hypersensitivity everolimus Excipient | Hypersensitivity Sirolimus Excipient
Item
known hypersensitivity to everolimus, sirolimus, or any of its excipients.
boolean
C0020517 (UMLS CUI [1,1])
C0541315 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0072980 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0541315 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0072980 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
patient is pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Comorbidity | Communicable Disease | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorder Protocol Compliance Limited | Social situation Protocol Compliance Limited
Item
patient has incurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
boolean
C0009488 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
C0004936 (UMLS CUI [6,1])
C0525058 (UMLS CUI [6,2])
C0439801 (UMLS CUI [6,3])
C0748872 (UMLS CUI [7,1])
C0525058 (UMLS CUI [7,2])
C0439801 (UMLS CUI [7,3])
Able to swallow RAD 001 Tablet
Item
patient is unable to swallow rad001 tablet.
boolean
C2712086 (UMLS CUI [1,1])
C0962969 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
invasive cancer | Skin carcinoma
Item
history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of the malignancy being present within the past five years.
boolean
C0677898 (UMLS CUI [1])
C0699893 (UMLS CUI [2])
Severe allergy docetaxel | Severe allergy Polysorbate 80 Pharmaceutical Preparations | Bronchial Spasm | Generalized urticaria | Systolic Pressure | Angioedema
Item
history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic bp ≤ 80mm hg, and angioedema.
boolean
C2945656 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0032601 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
C0006266 (UMLS CUI [3])
C0750016 (UMLS CUI [4])
C0871470 (UMLS CUI [5])
C0002994 (UMLS CUI [6])
Eligibility Determination Medical research personnel
Item
final eligibility for a clinical trial is determined by the health professionals conducting the trial.
boolean
C0013893 (UMLS CUI [1,1])
C3826005 (UMLS CUI [1,2])